Research & Education
CURE Expert Connections
To start your customized experience click the start button
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
MDS and MPN
Side Effect Management
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Immunotherapy Combination Improves Melanoma Outcomes, But at a Cost
Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) improved response rates in patients with melanoma, but not without some severe side effects.
Expert Discusses Immunotherapy's Expanding Role in Lung Cancer Treatment
Marina C. Garassino, M.D., talks about exciting advances in the field of lung cancer.
Immunotherapy Shows Promise for Mesothelioma Treatment
Clinical trials of combination immunotherapy treatments are showing impressive overall survival rates.
Immunotherapy Combination Sparks a Response in Melanoma Brain Metastases
The combination of the immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) sparked a response in nearly half of asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.
New Immunotherapy Shows Response for Metastatic Melanoma, Study Says
The longest response rate lasted six months.
Immunotherapy Offers New Optimism for Patients With Merkel Cell Carcinoma
Although chemotherapy has been used to treat patients with Merkel cell carcinoma, immunotherapy agents show great promise, according to findings presented at the 2017 World Congress of Melanoma.
Excitement Grows for Immunotherapy in Lung Cancer
A number of patients with lung cancer have benefitted from immunotherapy agents, and researchers in the field are excited that these treatments will continue to improve the field.
Breaking Down Misconceptions About Glioblastoma
David Reardon, M.D.
David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).
When to Stop Immunotherapy Treatment for Melanoma
Yania Jansen, surgical trainee at Vrije Universiteit Brussel, in Brussels, Belgium, discusses the possibility of stopping treatment with Keytruda (pembrolizumab) for patients with melanoma.
Immunotherapy: Seeking a Cure With Caution
Immunotherapy agents are promising in the treatment of cancer, but also come with some awful side effects.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
What is your status?
Out of Treatment